Eric Song
YOU?
Author Swipe
View article: Table S2 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
Table S2 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma Open
Supplementary Table S2: HLA genotype calls.
View article: Table S3 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
Table S3 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma Open
Supplementary Table S3: Predicted pathogenic/deleterious variants by exome sequencing.
View article: Table S4 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
Table S4 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma Open
Supplementary Table S4: Metadata annotations for the scRNA-seq dataset.
View article: Supplementary Figures from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
Supplementary Figures from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma Open
Supplementary Figure S1: Additional characterization of the clinical trial cohort.Supplementary Figure S2: Additional characterization of exome profiles and defining MLH1 methylation status.Supplementary Figure S3: JAK1 alterations are mos…
View article: Table S1 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
Table S1 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma Open
Supplementary Table S1: Genomic and clinical characteristics of the study cohort.
View article: Distinct oxytocin signaling pathways synergistically mediate rescue-like behavior in mice
Distinct oxytocin signaling pathways synergistically mediate rescue-like behavior in mice Open
Spontaneous rescue behavior enhances the well-being and survival of social animals, yet the neural mechanisms underlying the recognition and response to conspecifics in need remain unclear. Here, we report that observer mice experience dis…
View article: Th1 cells express Tfh effector molecules and associate with B cells at the T-B border following viral infection
Th1 cells express Tfh effector molecules and associate with B cells at the T-B border following viral infection Open
Antibodies protect the host from pathogens by neutralizing viruses, targeting pathogens for phagocytosis and complement deposition, and by activating innate immune cells. Most studies on the cellular mechanisms of antibody induction focus …
View article: Correction: Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling
Correction: Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling Open
View article: Figure S5 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma
Figure S5 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma Open
Figure S5: Evaluation of SETDB1 knockdown in human melanoma cells, related to Figure 4:
View article: Figure S6 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma
Figure S6 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma Open
Figure S6: Characterization of possible SKO tumor antigens, related to Figure 4.
View article: Table S4 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma
Table S4 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma Open
Differential expression of SKO vs YRG cells ± IFNAR blockade by RNAseq.
View article: Figure S4 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma
Figure S4 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma Open
Figure S4: Evaluation of differences in SKO tumor gene expression and microenvironment profiles, related to Figure 3:
View article: Table S2 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma
Table S2 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma Open
Ranked CRISPR screen dropout hits, related to Figure 1. Analysis was performed using MaGeCK.
View article: Data from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma
Data from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma Open
Despite recent advances in the treatment of melanoma, many patients with metastatic disease still succumb to their disease. To identify tumor-intrinsic modulators of immunity to melanoma, we performed a whole-genome CRISPR screen in melano…
View article: Figure S1 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma
Figure S1 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma Open
Figure S1: Experimental validation of SETDB1 knockout and flow gating schemes, related to Figure 4
View article: Table S3 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma
Table S3 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma Open
Differential expression of SKO vs YRG cells, by RNAseq.
View article: Figure S2 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma
Figure S2 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma Open
Figure S2: CRISPR screen guide distributions, related to Figure 1
View article: Figure S3 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma
Figure S3 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma Open
Figure S3: Validation and characterization of Setdb1-/- cell lines, tumors, and microenvironments, related to Figure 2.
View article: Table S5 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma
Table S5 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma Open
Summary of exonic mutations in YRG cells compared with YMG and WT C57BL6/J cells.
View article: Table S1 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma
Table S1 from <i>Setdb1</i> Loss Induces Type I Interferons and Immune Clearance of Melanoma Open
List of primers used to perform RT-qPCR on YUDOSO cells related to Figure S6.
View article: Anti-Syndecan 2 Antibody Treatment Reduces Edema Formation and Inflammation of Murine Laser-Induced CNV
Anti-Syndecan 2 Antibody Treatment Reduces Edema Formation and Inflammation of Murine Laser-Induced CNV Open
Intravitreal anti-Sdc2 treatment may avoid side effects observed with the long-term anti-VEGF therapy, and systemic treatment with an anti-Sdc2 pAb antibody can address the issues associated with repeated intravitreal injections.
View article: Monoclonal antibodies that block Roundabout 1 and 2 signaling target pathological ocular neovascularization through myeloid cells
Monoclonal antibodies that block Roundabout 1 and 2 signaling target pathological ocular neovascularization through myeloid cells Open
Roundabout (ROBO) 1 and 2 are transmembrane receptors that bind secreted SLIT ligands through their extracellular domains (ECDs) and signal through their cytoplasmic domains to modulate the cytoskeleton and regulate cell migration, adhesio…
View article: VEGF-C prophylaxis favors lymphatic drainage and modulates neuroinflammation in a stroke model
VEGF-C prophylaxis favors lymphatic drainage and modulates neuroinflammation in a stroke model Open
Meningeal lymphatic vessels (MLVs) promote tissue clearance and immune surveillance in the central nervous system (CNS). Vascular endothelial growth factor-C (VEGF-C) regulates MLV development and maintenance and has therapeutic potential …
View article: Compartmentalized ocular lymphatic system mediates eye–brain immunity
Compartmentalized ocular lymphatic system mediates eye–brain immunity Open
The eye, an anatomical extension of the central nervous system (CNS), exhibits many molecular and cellular parallels to the brain. Emerging research demonstrates that changes in the brain are often reflected in the eye, particularly in the…
View article: Haplotype-aware modeling of cis-regulatory effects highlights the gaps remaining in eQTL data
Haplotype-aware modeling of cis-regulatory effects highlights the gaps remaining in eQTL data Open
Expression Quantitative Trait Loci (eQTLs) are critical to understanding the mechanisms underlying disease-associated genomic loci. Nearly all protein-coding genes in the human genome have been associated with one or more eQTLs. Here we in…
View article: 708 A phase 1/2 study of rinatabart sesutecan (PRO1184), a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors
708 A phase 1/2 study of rinatabart sesutecan (PRO1184), a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors Open
Background Rinatabart sesutecan (Rina-S) is an antibody-drug conjugate (ADC) consisting of a human monoclonal antibody that selectively binds FRα, a novel cleavable hydrophilic linker, and a topoisomerase 1 inhibitor payload, exatecan. The…
View article: 718 Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies
718 Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies Open
Background PRO1160 is a novel antibody-drug conjugate (ADC) directed to CD70, an antigen mediating immuno-suppression that is overexpressed in multiple solid tumors and hematologic malignancies, with limited distribution in normal tissues.…
View article: Developing synthetic tools to decipher the tumor–immune interactome
Developing synthetic tools to decipher the tumor–immune interactome Open
The ability of immune cells to directly interact with transformed cells is an essential component of immune surveillance and critical for optimal tissue function. The tumor–immune interactome (the collective cellular interactions between o…
View article: Distinguishing features of long COVID identified through immune profiling
Distinguishing features of long COVID identified through immune profiling Open
Post-acute infection syndromes may develop after acute viral disease 1 . Infection with SARS-CoV-2 can result in the development of a post-acute infection syndrome known as long COVID. Individuals with long COVID frequently report unremitt…
View article: Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies
Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies Open
Background: PRO1160 is a novel antibody-drug conjugate (ADC) directed to CD70, an antigen mediating immuno-suppression that is overexpressed in multiple solid tumors and hematologic malignancies, with limited distribution in normal tissues…